ERBB2 and breast carcinoma: The study aims to investigate, using real-world data, if the application of one-year adjuvant trastuzumab, in cases of early HER2-positive breast cancer, is beneficial to the health outcomes of women concerning the costs (cost-effectiveness analysis).